Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11661422 Tricyclic urea compounds as JAK2 V617F inhibitors

Patent 11661422 was granted and assigned to Incyte on May, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Date of Patent

May 30, 2023

0

Patent Application Number

174126500

Date Filed

August 26, 2021

0

Patent Citations

US Patent 8785639 Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof

0

US Patent 9233985 Arginase inhibitors as therapeutics

0

US Patent 9321730 Method of making and administering quinoline derivatives as anti-cancer agents

0

US Patent 9493419 Quinoline derivatives as anti-cancer agents

0

US Patent 10065974 Compositions and methods for inhibiting arginase activity

0

US Patent 10155987 Methods of predicting resistance to JAK inhibitor therapy

0

US Patent 10377759 Brk inhibitory compound

0

US Patent 10287303 Compositions and methods for inhibiting arginase activity

0

...

Patent Citations Received

US Patent 12084430 Tricyclic urea compounds as JAK2 V617F inhibitors

0

Patent Primary Examiner

Charanjit Aulakh

0

CPC Code

0

0

The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11661422 Tricyclic urea compounds as JAK2 V617F inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool